TG Therapeutics (TGTX) Stock Price, News & Analysis

Company Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Key Stats

• Today's Range: $27.64 to $28.35
• 50-Day Range: $26.39 to $40.06
• 52-Week Range: $20.81 to $46.48
• Volume: 1.80 million shs
• Average Volume: 2.51 million shs
• Market Capitalization: $4.46 billion
• P/E Ratio: 75.89
• Dividend Yield: N/A
• Price Target: $46.25
• Consensus Rating: Moderate Buy

TG Therapeutics Stock Analysis - MarketRank™

TG Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 145th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

TG Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 1,150.00%

Earnings Growth

Earnings for TG Therapeutics are expected to grow by 1,150.00% in the coming year, from $0.08 to $1.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TG Therapeutics is 75.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of TG Therapeutics is 75.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.40.

Price to Book Value per Share Ratio

TG Therapeutics has a P/B Ratio of 16.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.53% of the float of TG Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TG Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.

Change versus previous month

Short interest in TG Therapeutics has recently decreased by 3.02%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TG Therapeutics does not currently pay a dividend.

Dividend Growth

TG Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.46

Percentage of Shares Shorted

16.53% of the float of TG Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TG Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.

Change versus previous month

Short interest in TG Therapeutics has recently decreased by 3.02%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.65

News Sentiment

TG Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for TG Therapeutics this week, compared to 8 articles on an average week.

Search Interest

15 people have searched for TGTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

5 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,400.00 in company stock.

Percentage Held by Insiders

10.64% of the stock of TG Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TGTX Stock Analysis - Frequently Asked Questions

How have TGTX shares performed this year?

TG Therapeutics' stock was trading at $30.10 at the beginning of the year. Since then, TGTX shares have decreased by 7.0% and is now trading at $28.0010.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) released its quarterly earnings results on Monday, August, 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by $0.15. The firm's revenue was up 92.1% on a year-over-year basis.
Read the conference call transcript.

Who are TG Therapeutics' major shareholders?

Top institutional shareholders of TG Therapeutics include State Street Corp (4.80%), Geode Capital Management LLC (2.20%), Hood River Capital Management LLC (0.99%) and Invesco Ltd. (0.61%). Insiders that own company stock include Michael S Weiss, Sean A Power, Yann Echelard, Laurence N Charney and Sagar Lonial.
View institutional ownership trends.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TG Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/04/2025
• Today: 8/15/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TGTX
• CIK: 1001316
• Web: www.tgtherapeutics.com
• Phone: (212) 554-4484
• Fax: 212-554-4531
• Employees: 290
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TG Therapeutics: $46.25
• High Price Target: $55.00
• Low Price Target: $37.00
• Potential Upside/Downside: +66.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.37
• Trailing P/E Ratio: 75.05
• Forward P/E Ratio: 347.13
• P/E Growth: N/A
• Net Income: $23.38 million
• Net Margins: 13.31%
• Pretax Margin: 14.56%
• Return on Equity: 26.05%
• Return on Assets: 9.58%

Debt

• Debt-to-Equity Ratio: 0.89
• Current Ratio: 3.86
• Quick Ratio: 3.04

Sales & Book Value

• Annual Sales: $329 million
• Price / Sales: 13.39
• Cash Flow: $0.12 per share
• Price / Cash Flow: 232.32
• Book Value: $1.74 per share
• Price / Book: 15.96

Miscellaneous

• Outstanding Shares: 158,670,000
• Free Float: 141,784,000
• Market Cap: $4.41 billion
• Optionable: Optionable
• Beta: 1.95